Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Accumulated Expenses: 2022-2024

Historic Accumulated Expenses for Centessa Pharmaceuticals (CNTA) over the last 3 years, with Dec 2024 value amounting to $50.9 million.

  • Centessa Pharmaceuticals' Accumulated Expenses rose 7.78% to $20.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.4 million, marking a year-over-year increase of 7.78%. This contributed to the annual value of $50.9 million for FY2024, which is 84.46% up from last year.
  • Latest data reveals that Centessa Pharmaceuticals reported Accumulated Expenses of $50.9 million as of FY2024, which was up 84.46% from $27.6 million recorded in FY2023.
  • In the past 5 years, Centessa Pharmaceuticals' Accumulated Expenses ranged from a high of $50.9 million in FY2024 and a low of $24.5 million during FY2022.
  • For the 3-year period, Centessa Pharmaceuticals' Accumulated Expenses averaged around $34.3 million, with its median value being $27.6 million (2023).
  • Data for Centessa Pharmaceuticals' Accumulated Expenses shows a peak YoY soared of 84.46% (in 2024) over the last 5 years.
  • Centessa Pharmaceuticals' Accumulated Expenses (Yearly) stood at $24.5 million in 2022, then climbed by 12.52% to $27.6 million in 2023, then skyrocketed by 84.46% to $50.9 million in 2024.